Strategic Focus Eleusis is a clinical-stage biotechnology firm dedicated to psychedelics for psychiatric and broader therapeutic applications, presenting opportunities to partner on early to mid-stage clinical studies, companion diagnostics, and care delivery design aligned with psychedelics development.

Clinical Capabilities With in-house discovery and development plus Andala’s care delivery platform, Eleusis seeks end-to-end solutions from drug discovery through patient care, offering potential collaborations in trial design, regulatory strategy, and real-world data capture for neuroscience indications.

Intellectual Property Eleusis has pursued proprietary psilocin salt formulations and related IP, signaling opportunities to license or co-develop novel psychedelic delivery and formulation strategies, as well as potential collaboration on IP-driven differentiation in psychiatry targets.

Strategic Partnerships Past activity includes acquisitions and leadership hires in pharmacology and board governance, indicating openness to strategic alliances, licensing deals, and joint ventures with mid to large biotech players or specialty pharma seeking psychedelics competencies.

Market Readiness As a low- to mid-headcount clinical-stage player with measurable revenue and limited funding rounds, Eleusis could benefit from partnerships that accelerate development timelines, scale manufacturing, and de-risk programs through shared clinical and operational resources.